Abstract
The possibility to use a family donor sharing only one haplotype with recipient affected by hematological malignancy has been searched from many years because it allows having a donor in every case for every patient. At the beginning, this kind of transplantation was considered too toxic, but after the development of specific strategies of conditioning regimens and ex vivo T-cell depletion, its feasibility and efficacy has been proved, mainly for acute leukemia. However, these haploidentical programs with ex vivo T-cell depletion need of sophisticated and dedicated laboratories and are characterized by frequent infectious complications and relapse, because of delayed immune reconstitution. For these reasons, many groups have developed alternative program for haploidentical transplantation, without ex vivo T-cell depletion, obtaining encouraging results in haematological malignancies. In this review, we analyze data produced by different groups, underscoring their principal characteristics.
Translated title of the contribution | Advances in haploidentical transplantation in hematological malignancies |
---|---|
Original language | French |
Pages (from-to) | 1141-1151 |
Number of pages | 11 |
Journal | Bulletin du Cancer |
Volume | 99 |
Issue number | 12 |
DOIs | |
Publication status | Published - Dec 2012 |
Keywords
- Haploidentical transplantation
- Hematological malignancies
- Myeloablative conditioning regimens
- Reduced intensity conditioning regimens
ASJC Scopus subject areas
- Oncology
- Cancer Research
- Radiology Nuclear Medicine and imaging
- Hematology